()() chairman Gabriele Cerrone speaks to Proactive's Andrew Scott after data on its StemPrintER breast cancer prognostic test was presented at the American Society of Clinical Oncology Virtual Conference.
He says the study demonstrated 'greater refinement and superiority of StemPrintER' over current market leader Oncotype DX in delivering prognostic information as part of the therapeutic decision-making process in ER+/HER2- breast cancer patients.
Cerrone says the findings are made all the more significant given the move last year by () which paid $2.8bn to buy out Genomic Health because of its Oncotype DX technology.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE